Literature DB >> 6207909

In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells.

M Namba, S Yamamoto, H Tanaka, T Kanamori, M Nobuhara, T Kimoto.   

Abstract

A possibility that interferon may potentiate the cytotoxic effects of anticancer drugs or 60Co gamma ray on human neoplastic cells was studied by in vitro and in vivo experimental procedures. The human neoplastic cells used were HeLa (uterine cervical cancer) and WI-38 CT-1 (embryonic lung fibroblasts transformed in culture by 60Co gamma ray) cells. As normal human cells, WI-38 cells were used. Interferon was a preparation of beta-type produced by human fibroblasts. The cytotoxicity was determined by colony formation for in vitro experiments and by tumor growth for animal experiments. Of 17 anticancer drugs, the cytotoxic effects of six drugs, namely, peplomycin, bleomycin, aclacinomycin, cisplatin, 5-fluorouracil (5-FU), and Adriamycin (doxorubicin) were potentiated by concomitant application of interferon. The cytolethal effects of 60Co gamma ray were also enhanced by interferon. The growth of tumor induced by transplantation of HeLa cells into a nude mouse was remarkably reduced by combination therapy of interferon and 5-FU. The current results indicate a possibility that combined therapy of certain types of anticancer drugs or 60Co gamma ray with interferon may be effective in treatment of cancer patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207909     DOI: 10.1002/1097-0142(19841115)54:10<2262::aid-cncr2820541033>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Interferons: current status and future directions of this prototypic biological.

Authors:  R V Smalley; E C Borden
Journal:  Springer Semin Immunopathol       Date:  1986

2.  Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma.

Authors:  G Visani; R M Lemoli; P Tosi; F Verlicchi; B Gamberi; A R Cenacchi; R Colombini; M Fogli; D Russo; E Zuffa
Journal:  Blut       Date:  1990-05

3.  The role of alpha interferon in the biomodulation of disease: preface.

Authors:  S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

4.  Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer.

Authors:  P I Clark; M L Slevin; R H Reznek; N Niederle; E Kurschel; G Lundell; B Cedermark; A Fallenius; H Blomgren; U Ohman
Journal:  Int J Colorectal Dis       Date:  1987-02       Impact factor: 2.571

5.  Antitumor activity of new anthracycline analogues in combination with interferon alfa.

Authors:  M E Berens; T Saito; C E Welander; E J Modest
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

Authors:  H O Klein; G Golbach; P Voigt; C Coerper; C Bernhardt
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.

Authors:  E E Vokes; D J Haraf; P C Hoffman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

9.  A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.

Authors:  E E Vokes; D J Haraf; L C Drinkard; P C Hoffman; M K Ferguson; N J Vogelzang; S Watson; N J Lane; H M Golomb
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.